The history of human sleeping sickness in East Africa is characterized by the appearance of
disease epidemics interspersed by long periods of endemicity. Despite the presence of the …

Resistance to currently used drugs is a serious problem in most fields of antimicrobial
chemotherapy. Crossresistance between two of the major classes of drug used in the …

Sleeping sickness, or human A f rican try panosomiasis (H AT), is back. 1, 2 T h at was the
message from an inte rn ational gat he ring of delegates at a meeting held by the Institute of …

The bloodstream stage of Trypanosoma brucei and probably the intracellular (amastigote)
stage of Trypanosoma cruzi derive all of their energy from glycolysis. Inhibiting glycolytic …

Adenosine influx by Trypanosoma brucei brucei P1 and P2 transporters was kinetically
characterized. The P1 transporter displayed a higher affinity and capacity for adenosine (K …

We evaluated the treatment failure rate among late-stage human African trypanosomiasis
(HAT) patients treated with melarsoprol in Arua, northern Uganda, between September 1995 …

The leaves and the root extracts of Moringa stenopetala were tested in vitro against
trypomastigotes of Trypanosoma brucei, Trypanosoma cruzi and L. donovani amastigotes …

There is an urgent need for new drugs for the chemotherapy of human African
trypanosomiasis, Chagas disease and leishmaniasis. Progress has been made in the …

Almost a century after the introduction of Atoxyl® in 1905, the ideal antitrypanosomal drug,
that should be cheap, effective in early and advanced sleeping sickness, of low toxicity, with …

A 36‐kDa protein was isolated by affinity chromatography using Cymelarsan, an arsenical
drug currently used in African trypanosomiasis treatment, as ligand. This protein was …